Kimberly-Clark cuts annual forecasts as China disruption weighs on diaper sales
Kimberly-Clark cut its 2026 sales and profit forecasts after a China disruption hurt second-quarter diaper demand. The company said social media claims that Huggies diapers contained toxic formamide weighed on sales despite third-party testing confirming quality. China’s regulator announced a joint investigation on June 22. Net sales were $4.19B vs $4.22B expected.
How this was made
The 30-second read
Why it matters
The company linked the disruption to weaker second-quarter sales and lowered full-year organic growth and adjusted EPS growth expectations, signaling higher uncertainty for near-term earnings power.
Market read
Guidance reduction tied to a China regulatory/demand shock is a fresh, company-specific catalyst that can drive estimate revisions and near-term trading flows.
What to watch
North America volume softness is also cited (inflation-driven consumer pullback), so China may not be the only driver of estimate pressure.
Background
Kimberly-Clark is navigating a China disruption after social-media allegations about formamide in Huggies diapers, while China’s regulator launched a joint investigation without naming a brand.
Ticker impact
Kimberly-Clark cut annual sales and profit forecasts, citing a China hit from toxic-formamide diaper claims despite third-party testing.
Bearish bias for near-term estimates until China investigation outcomes or demand stabilization emerge.
The article reports a direct guidance reduction with a specific causal chain to China demand and an ongoing regulator probe, which typically pressures valuation and revisions.
Market effects
Highlights regulatory and social-media claim risk for packaged baby-care brands, potentially raising diligence and contingency planning across consumer staples.
China demand uncertainty for diapers and related categories could drive broader caution on China-exposed consumer names.
If the China probe escalates, it can spill into cross-border brand trust and supply-chain scrutiny for multinational consumer goods.
Counterpoint
If independent testing remains credible and the regulator investigation resolves without sanctions, the guidance cut may prove conservative and revisions could rebound.
Key entities
- companyKimberly-Clark
Kleenex and Huggies maker that cut annual sales and profit forecasts due to China demand hit and an ongoing regulator investigation.
- regulatorChina’s market regulator
Announced a joint investigation into alleged formamide issues in infant diapers; no update provided in the article.
- companyKenvue
Kimberly-Clark’s roughly $40 billion acquisition is on track to close by year-end, mentioned alongside the forecast cut.
- companySuzano
Buyer of a 51% stake in Kimberly-Clark’s international tissue business, tied to the Arbex joint venture context.
